CREATE Medicines (Series B)
Funding Details
Awarder
Inbox
Date Award
May 14, 2026
Vertical
Biotechnology
Funding Amount
$122,000,000
Company Info
Founders
Daniel Getts, PhD
Market
Immunotherapy
Location
Cambridge, MA, USA
Coinvestors
Alexandria Venture Investments, ARCH Venture Partners, Hatteras Venture Partners, Newpath Partners
Company Description

CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly engineers T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. CREATE is advancing a pipeline of in vivo CAR therapies across autoimmune diseases and cancer.

Links